SUV for tumor [A], brain [B] and liver [C] 4 and 24 h after treatment with ASA 404. Small animal FDG-PET imaging (frontal and saggital sections) 4 h after treatment with taxol [E], ASA404 [F] or TAX + ASA404 [G]. [D] represents an untreated control. The treatment of animals with ASA404 caused a marked decrease of the 18 F-FDG uptake which existed also 24 h after treatment with same compound. In case of combined therapy the same effect was observed. No significant change of 18 F-FDG uptake was observed in the brain [Figure 4B] and the liver [Figure 4C] in ASA404 treated animals in comparison to untreated control. The treatment with taxol as a sole compound did not influence significant change of SUVs.